COCRYSTAL PHARMA NEW O.N. (8CC) - Total Liabilities
Based on the latest financial reports, COCRYSTAL PHARMA NEW O.N. (8CC) has total liabilities worth €3.38 Million EUR (≈ $3.95 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 8CC current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
COCRYSTAL PHARMA NEW O.N. - Total Liabilities Trend (2021–2025)
This chart illustrates how COCRYSTAL PHARMA NEW O.N.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see COCRYSTAL PHARMA NEW O.N. assets under control.
COCRYSTAL PHARMA NEW O.N. Competitors by Total Liabilities
The table below lists competitors of COCRYSTAL PHARMA NEW O.N. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SPAR Group Inc
NASDAQ:SGRP
|
USA | $45.08 Million |
|
East Africa Metals Inc.
V:EAM
|
Canada | CA$4.50 Million |
|
Youngsin Metal Industrial Co. Ltd
KQ:007530
|
Korea | ₩106.30 Billion |
|
Pharma Equity Group A/S Cl A
CO:PEG
|
Denmark | Dkr13.43 Million |
|
PeterLabs Holdings Bhd
KLSE:0171
|
Malaysia | RM21.70 Million |
|
Niocan Inc
V:NIO
|
Canada | CA$216.05K |
|
Swvl Holdings Corp
NASDAQ:SWVL
|
USA | $17.53 Million |
|
Initiator Pharma A/S
ST:INIT
|
Sweden | Skr4.37 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down COCRYSTAL PHARMA NEW O.N.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of COCRYSTAL PHARMA NEW O.N. to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how COCRYSTAL PHARMA NEW O.N.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for COCRYSTAL PHARMA NEW O.N. (2021–2025)
The table below shows the annual total liabilities of COCRYSTAL PHARMA NEW O.N. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €3.38 Million ≈ $3.95 Million |
-14.04% |
| 2024-12-31 | €3.93 Million ≈ $4.60 Million |
-19.32% |
| 2023-12-31 | €4.88 Million ≈ $5.70 Million |
+282.95% |
| 2022-12-31 | €1.27 Million ≈ $1.49 Million |
-30.93% |
| 2021-12-31 | €1.84 Million ≈ $2.15 Million |
-- |
About COCRYSTAL PHARMA NEW O.N.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hep… Read more